 SOUTH SAN FRANCISCO, Calif., June 15, 2021 GLOBE NEWSWIRE -- RAPT Therapeutics, Inc. Nasdaq: RAPT, a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 3,787,879 shares of its common stock at a price to the public of 33.00 per share. All of the shares of common stock are being offered by RAPT. Gross proceeds to RAPT from the offering are expected to be approximately 125 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 568,181 shares of common stock on the same terms and conditions. The offering is expected to close on June 18, 2021, subject to customary closing conditions. 